EA201071268A1 - СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА erbB - Google Patents
СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА erbBInfo
- Publication number
- EA201071268A1 EA201071268A1 EA201071268A EA201071268A EA201071268A1 EA 201071268 A1 EA201071268 A1 EA 201071268A1 EA 201071268 A EA201071268 A EA 201071268A EA 201071268 A EA201071268 A EA 201071268A EA 201071268 A1 EA201071268 A1 EA 201071268A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inhibitor
- erbb
- cmet
- treatment method
- cancer treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Данное изобретение относится к способу лечения рака у пациента, включающего введение пациенту терапевтически эффективных количеств (а) соединения формулы А или фармацевтически приемлемой соли указанного соединения; где R-R, р и q имеют указанные значения, и (b) ингибитора erbB, который ингибирует рецептор erbB-1, или eгbB-2, или erbB-3, или их комбинацию. Способ по данному изобретению обращен на потребности в области техники, связанной с открытием комбинированной терапии, которая, как очевидно показано, является более эффективной терапией, чем ранее описанные терапии.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5032208P | 2008-05-05 | 2008-05-05 | |
PCT/US2009/042768 WO2009137429A1 (en) | 2008-05-05 | 2009-05-05 | Method of treating cancer using a cmet and axl inhibitor and an erbb inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201071268A1 true EA201071268A1 (ru) | 2011-06-30 |
EA020779B1 EA020779B1 (ru) | 2015-01-30 |
Family
ID=41257222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201071268A EA020779B1 (ru) | 2008-05-05 | 2009-05-05 | СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА ErbB |
Country Status (19)
Country | Link |
---|---|
US (3) | US20090274693A1 (ru) |
EP (1) | EP2274304A4 (ru) |
JP (1) | JP2011519941A (ru) |
KR (1) | KR20110004462A (ru) |
CN (1) | CN102083824A (ru) |
AR (1) | AR071631A1 (ru) |
AU (1) | AU2009244453B2 (ru) |
BR (1) | BRPI0912582A2 (ru) |
CA (1) | CA2723699A1 (ru) |
CL (1) | CL2009001063A1 (ru) |
EA (1) | EA020779B1 (ru) |
IL (1) | IL209057A0 (ru) |
MX (1) | MX2010012101A (ru) |
PE (1) | PE20091832A1 (ru) |
SG (1) | SG190623A1 (ru) |
TW (1) | TW201006829A (ru) |
UY (1) | UY31800A (ru) |
WO (1) | WO2009137429A1 (ru) |
ZA (1) | ZA201007722B (ru) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2833706C (en) | 2005-11-11 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Quinazoline derivatives for the treatment of cancer diseases |
EA019959B1 (ru) | 2009-01-16 | 2014-07-30 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее кристаллические формы для лечения рака |
BRPI1006448B1 (pt) | 2009-03-25 | 2021-08-17 | Genentech, Inc | Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3 |
LT2451445T (lt) | 2009-07-06 | 2019-06-25 | Boehringer Ingelheim International Gmbh | Bibw2992, jo druskų ir kietų farmacinių kompozicijų, apimančių šį aktyvųjį ingredientą, džiovinimo būdas |
AR077595A1 (es) * | 2009-07-27 | 2011-09-07 | Genentech Inc | Tratamientos de combinacion |
WO2011014872A2 (en) * | 2009-07-31 | 2011-02-03 | The Johns Hopkins University | Compositions and methods for diagnosing, treating or preventing neoplasias |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
ES2655737T3 (es) * | 2009-11-13 | 2018-02-21 | Daiichi Sankyo Europe Gmbh | Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3 |
EA030435B1 (ru) | 2010-07-16 | 2018-08-31 | Экселиксис, Инк. | ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ |
UA114883C2 (uk) | 2010-08-20 | 2017-08-28 | Новартіс Аг | Антитіло до рецептора епідермального фактора росту-3 (her3) |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
SG191230A1 (en) * | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
CN102532109B (zh) * | 2010-12-27 | 2015-05-13 | 浙江海正药业股份有限公司 | 一种拉帕替尼及其盐的合成方法 |
CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
KR20210147117A (ko) | 2011-02-10 | 2021-12-06 | 엑셀리시스, 인코포레이티드 | 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
CA2834778C (en) * | 2011-05-02 | 2019-08-13 | Exelixis, Inc. | Method of treating cancer and bone cancer pain |
WO2013043840A1 (en) | 2011-09-22 | 2013-03-28 | Exelixis, Inc. | Method for treating osteoporosis |
HUE048023T2 (hu) | 2011-10-20 | 2020-05-28 | Exelixis Inc | Eljárás kinolin-származékok elõállítására |
EP3045453A1 (en) * | 2011-11-14 | 2016-07-20 | Cephalon, Inc. | Uracil derivatives as axl and c-met kinase inhibitors |
UY34487A (es) * | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3) |
TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
SI2810937T1 (sl) | 2012-01-31 | 2017-01-31 | Daiichi Sankyo Company, Limited | Derivat piridona |
US9861624B2 (en) | 2012-05-02 | 2018-01-09 | Exelixis, Inc. | Method of treating cancer |
CN103664879A (zh) * | 2012-09-17 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
CN103705521A (zh) * | 2012-09-28 | 2014-04-09 | 韩冰 | 一类治疗脑梗塞的化合物及其用途 |
WO2014093750A1 (en) * | 2012-12-14 | 2014-06-19 | Glaxosmithkline Llc | Method of administration and treatment |
EP2970126B1 (en) | 2013-03-15 | 2019-03-06 | Exelixis, Inc. | Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
US11564915B2 (en) | 2013-04-04 | 2023-01-31 | Exelixis, Inc. | Cabozantinib dosage form and use in the treatment of cancer |
TWI649308B (zh) * | 2013-07-24 | 2019-02-01 | 小野藥品工業股份有限公司 | 喹啉衍生物 |
BR112016008125B1 (pt) | 2013-10-14 | 2023-11-21 | Janssen Biotech, Inc. | Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína |
SI3103453T1 (sl) | 2014-02-04 | 2020-10-30 | Astellas Pharma Inc. | Medicinski sestavek, ki obsega diamino heterociklično karboksamidno spojino kot aktivno sestavino |
EP3738952A1 (en) | 2014-02-14 | 2020-11-18 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
MA39735A (fr) | 2014-03-17 | 2017-01-25 | Exelixis Inc | Dosage de préparations de cabozantinib |
RU2733401C2 (ru) * | 2014-04-03 | 2020-10-01 | Мерк Патент Гмбх | Комбинации противораковых лекарств |
KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
TWI690525B (zh) | 2014-07-07 | 2020-04-11 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
JP6892381B2 (ja) | 2014-08-05 | 2021-06-23 | エグゼリクシス, インコーポレイテッド | 多発性骨髄腫を治療するための薬物の組み合わせ |
EP3239147B9 (en) | 2014-12-25 | 2020-01-08 | Ono Pharmaceutical Co., Ltd. | Quinoline derivative |
FR3039401B1 (fr) * | 2015-07-31 | 2018-07-13 | Les Laboratoires Servier | Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr |
CN106467541B (zh) * | 2015-08-18 | 2019-04-05 | 暨南大学 | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 |
CA3020749A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
US10662235B2 (en) | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
CN107235896B (zh) * | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
CN107235897B (zh) * | 2016-09-27 | 2019-08-16 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
BR112019012154A2 (pt) | 2016-12-14 | 2019-11-12 | Janssen Biotech Inc | domínios do tipo iii da fibronectina de ligação a cd8a |
EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
EP3575293B1 (en) | 2017-01-26 | 2021-03-10 | ONO Pharmaceutical Co., Ltd. | Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide |
KR102323255B1 (ko) | 2017-02-15 | 2021-11-08 | 다이호야쿠힌고교 가부시키가이샤 | 의약 조성물 |
US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | ARO Biotherapeutics Company | FIBRONECTIN TYPE III DOMAINS BINDING TO CD137 |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
CN115073367A (zh) * | 2021-03-16 | 2022-09-20 | 南京科默生物医药有限公司 | 一种用作axl抑制剂的抗肿瘤化合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60203260T2 (de) * | 2001-01-16 | 2006-02-02 | Glaxo Group Ltd., Greenford | Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs |
ATE532782T1 (de) * | 2003-09-26 | 2011-11-15 | Exelixis Inc | C-met-modulatoren und anwendungsverfahren |
ITRM20030475A1 (it) * | 2003-10-15 | 2005-04-16 | Sipa Societa Industrializzazione P Rogettazione E | Impianto e metodo per il condizionamento termico di oggetti |
UA96139C2 (ru) * | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитело к нейропилину-1 (nrp1) |
JP5179373B2 (ja) * | 2005-12-15 | 2013-04-10 | アストラゼネカ アクチボラグ | 癌を治療するためのアンジオポエチン−2アンタゴニストとVEGF−A、KDR、及び/又はFlt1アンタゴニストの組合せ |
US20080058312A1 (en) * | 2006-01-11 | 2008-03-06 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
AU2007334402B2 (en) * | 2006-12-14 | 2014-02-13 | Exelixis, Inc. | Methods of using MEK inhibitors |
US8715665B2 (en) * | 2007-04-13 | 2014-05-06 | The General Hospital Corporation | Methods for treating cancer resistant to ErbB therapeutics |
EP2158215B1 (en) * | 2007-05-17 | 2015-04-22 | Genentech, Inc. | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
EP2200431B1 (en) * | 2007-09-10 | 2016-07-20 | Boston Biomedical, Inc. | Novel compositions and methods for cancer treatment |
-
2009
- 2009-04-30 UY UY0001031800A patent/UY31800A/es not_active Application Discontinuation
- 2009-05-04 CL CL2009001063A patent/CL2009001063A1/es unknown
- 2009-05-04 TW TW098114669A patent/TW201006829A/zh unknown
- 2009-05-04 PE PE2009000602A patent/PE20091832A1/es not_active Application Discontinuation
- 2009-05-05 EP EP09743415A patent/EP2274304A4/en not_active Withdrawn
- 2009-05-05 WO PCT/US2009/042768 patent/WO2009137429A1/en active Application Filing
- 2009-05-05 AU AU2009244453A patent/AU2009244453B2/en not_active Ceased
- 2009-05-05 BR BRPI0912582-5A patent/BRPI0912582A2/pt not_active IP Right Cessation
- 2009-05-05 JP JP2011508584A patent/JP2011519941A/ja active Pending
- 2009-05-05 CN CN2009801261595A patent/CN102083824A/zh active Pending
- 2009-05-05 AR ARP090101611A patent/AR071631A1/es unknown
- 2009-05-05 KR KR1020107027183A patent/KR20110004462A/ko not_active Application Discontinuation
- 2009-05-05 US US12/435,473 patent/US20090274693A1/en not_active Abandoned
- 2009-05-05 EA EA201071268A patent/EA020779B1/ru not_active IP Right Cessation
- 2009-05-05 MX MX2010012101A patent/MX2010012101A/es not_active Application Discontinuation
- 2009-05-05 SG SG2013033709A patent/SG190623A1/en unknown
- 2009-05-05 CA CA2723699A patent/CA2723699A1/en not_active Abandoned
-
2010
- 2010-10-28 ZA ZA2010/07722A patent/ZA201007722B/en unknown
- 2010-11-01 IL IL209057A patent/IL209057A0/en unknown
-
2013
- 2013-01-29 US US13/753,146 patent/US20130150363A1/en not_active Abandoned
- 2013-01-29 US US13/753,031 patent/US20130142790A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG190623A1 (en) | 2013-06-28 |
KR20110004462A (ko) | 2011-01-13 |
PE20091832A1 (es) | 2009-12-25 |
AR071631A1 (es) | 2010-06-30 |
UY31800A (es) | 2009-11-10 |
MX2010012101A (es) | 2010-11-30 |
US20130150363A1 (en) | 2013-06-13 |
US20090274693A1 (en) | 2009-11-05 |
AU2009244453A1 (en) | 2009-11-12 |
EP2274304A4 (en) | 2012-05-30 |
BRPI0912582A2 (pt) | 2015-07-28 |
JP2011519941A (ja) | 2011-07-14 |
CL2009001063A1 (es) | 2010-09-24 |
AU2009244453B2 (en) | 2012-07-19 |
EA020779B1 (ru) | 2015-01-30 |
ZA201007722B (en) | 2011-08-31 |
EP2274304A1 (en) | 2011-01-19 |
CA2723699A1 (en) | 2009-11-12 |
CN102083824A (zh) | 2011-06-01 |
TW201006829A (en) | 2010-02-16 |
IL209057A0 (en) | 2011-01-31 |
WO2009137429A1 (en) | 2009-11-12 |
US20130142790A1 (en) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201071268A1 (ru) | СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА erbB | |
TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
EA201101507A1 (ru) | Способы лечения солидных опухолей | |
RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
RU2012140185A (ru) | Ингибирование ангиогенеза | |
EA201290184A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
EA201391568A1 (ru) | Новые производные имидазола, подходящие для лечения артрита | |
EA200801041A1 (ru) | Ингибиторы мек и способы их применения | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
EA201300558A1 (ru) | Соединения и способы для купирования боли | |
RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
HK1120441A1 (en) | Drugs for treatment of ovarian cancer | |
EA201290138A1 (ru) | Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция | |
EA200800538A1 (ru) | Терапевтические соединения | |
EA201270373A1 (ru) | Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли | |
EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
EA201290139A1 (ru) | Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких | |
EA201290516A1 (ru) | Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
EA201101533A1 (ru) | Гетероциклические соединения в качестве ингибиторов mek | |
EA201290517A1 (ru) | Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a | |
EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА | |
EA201390428A1 (ru) | Композиции и способы лечения легочной гипертензии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |